Department of Ophthalmology, Mater Misericordiae University Hospital, Dublin, Ireland.
Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Ir J Med Sci. 2023 Dec;192(6):3163-3167. doi: 10.1007/s11845-023-03351-4. Epub 2023 Mar 27.
The Age-Related Eye Disease Study 2 (AREDS 2) proved the benefit of vitamin and mineral supplementation in preventing advanced age-related macular degeneration (AMD). AREDS 2 supplements are indicated for patients with either bilateral intermediate AMD (AREDS category 3) or unilateral neovascular AMD (AREDS category 4).
The aims of this telephone survey were to identify the rate of adherence of patients to AREDS 2 supplements and the factors associated with non-compliance in these patient groups.
A patient telephone survey was conducted in an Irish tertiary care hospital. Patients were identified by chart review, and their AREDS categorization was reconfirmed. A telephone consultation was conducted with each patient to assess their compliance with the micronutrient supplements.
We identified 120 patients who met the AREDS criteria for supplementation. Of these, 103 patients were graded as category 4, and 17 patients were graded as category 3. Almost a fifth (18%) were current smokers. Under two-thirds (60%) of the patients were taking AREDS 2 supplements. Of the remainder, 83% of patients did not recall being advised of their benefit. The cost was cited by 10% of patients as a reason for non-compliance.
The ophthalmologist not only has a duty of care to treat the neovascular complications of AMD, but they must also strive to improve patient compliance with AREDS supplements. The cessation of smoking needs to be actively promoted in order to stop preventable vision loss in patients with AMD.
年龄相关性眼病研究 2 期（AREDS2）证实了维生素和矿物质补充剂在预防晚期年龄相关性黄斑变性（AMD）方面的益处。AREDS2 补充剂适用于患有双侧中期 AMD（AREDS 类别 3）或单侧新生血管性 AMD（AREDS 类别 4）的患者。
本电话调查旨在确定患者对 AREDS2 补充剂的依从率，以及这些患者群体中不依从的相关因素。
在爱尔兰的一家三级保健医院进行了一项患者电话调查。通过病历回顾确定患者，并重新确认他们的 AREDS 分类。对每位患者进行电话咨询，以评估他们对微量营养素补充剂的依从性。
我们确定了 120 名符合 AREDS 补充标准的患者。其中，103 名患者被评为 4 类，17 名患者被评为 3 类。近五分之一（18%）的患者是当前吸烟者。不到三分之二（60%）的患者正在服用 AREDS2 补充剂。其余的患者中，83%的人不记得曾被建议服用该补充剂。10%的患者认为费用是不依从的原因。
眼科医生不仅有责任治疗 AMD 的新生血管并发症，还必须努力提高患者对 AREDS 补充剂的依从性。为了阻止 AMD 患者的可预防视力丧失，需要积极提倡戒烟。
